---
title: "AstraZeneca PLC (AZN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/AZN.US.md"
symbol: "AZN.US"
name: "AstraZeneca PLC"
industry: "制药"
---

# AstraZeneca PLC (AZN.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.astrazeneca.com](https://www.astrazeneca.com) |

## Company Profile

阿斯利康公司（AstraZeneca PLC）是一家生物制药公司，专注于处方药的发现、开发、生产和商业化。该公司提供的产品包括 Imjudo、Datroway、Iressa、Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Truqap、Zoladex、Faslodex、Farxiga、Brilinta、Crestor、Seloken、Lokelma、Roxadustat、Andexxa、Wainua、Symbicort、Fasenra、Pulmicort、Breztri/Trixeo、Saphnelo、Tezspire、Airsupra...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: B (0.38)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.63% |  |
| Net Profit YoY | 45.34% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.65 |  |
| Dividend Ratio | 1.50% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 323.56B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 58.74B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 22.86% | A |
| Profit Margin | 17.41% | A |
| Gross Margin | 81.66% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.63% | B |
| Net Profit YoY | 45.34% | B |
| Total Assets YoY | 9.65% | B |
| Net Assets YoY | 19.20% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 574.46% | C |
| OCF YoY | 8.63% | B |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.54 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 57.29% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - AstraZeneca PLC",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "22.86%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "17.41%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "81.66%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.63%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "45.34%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.65%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "19.20%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "574.46%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "8.63%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "57.29%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 31.64 | 42/257 | 31.33 | 29.92 | 28.26 |
| PB | 6.65 | 156/257 | 6.15 | 5.63 | 5.29 |
| PS (TTM) | 5.51 | 98/257 | 4.86 | 4.37 | 3.99 |
| Dividend Yield | 1.50% | 26/257 | 2.15% | 1.97% | 1.69% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-18T05:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 67% |
| Overweight | 2 | 22% |
| Hold | 0 | 0% |
| Underweight | 1 | 11% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 72.12 |

## References

- [Company Overview](https://longbridge.com/en/quote/AZN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/AZN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/AZN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.